Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.

Date publication

juillet 2026

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PEIGNAUX Karine

Tous les auteurs :
Kaidar-Person O, Weltens CG, Fortpied C, Scheijmans LJEE, Kirkove CY, Budach V, Peignaux-Casasnovas K, Valli M, Peters M, van der Leij F, Rivera S, Weidner N, van den Bongard DHJG, Linsenmeier C, Abdah-Bortnyak R, Hosni S, Koiter E, Engelen AM, Baten A, Champezou L, Fourquet A, Bartelink HGMM, Struikmans H, Poortmans PMP,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42372743

Résumé

Results from several studies, including our 15-year analysis, showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on overall survival with the addition of partial or comprehensive regional lymph node irradiation after surgery in patients with breast cancer. Here, we present the scheduled 20-year analysis of the EORTC trial 22922/10925, evaluating the role of internal mammary and medial-supraclavicular (IM-MS) nodal irradiation in patients with stage I-III breast cancer. Patients without confirmed axillary nodal involvement (pathological N stage 0 [pN0]) were eligible for the trial when the primary tumours were centrally or medially located.

Mots clés

Humans, Female, Breast Neoplasms, pathology, Middle Aged, Neoplasm Staging, Aged, Adult, Lymphatic Metastasis, Disease-Free Survival, Lymphatic Irradiation, adverse effects, Lymph Nodes, radiation effects, Adenocarcinoma, radiotherapy, Treatment Outcome, Radiotherapy, Adjuvant, Time Factors

Référence

Lancet Oncol. 2026 07;27(7):817-829